Men at ‘high’ skeletal risk prior to prostate cancer hormone therapy likely to have more fractures after treatment

In what is believed to be the first study to describe the impact on men with a ‘high’ risk of bone fracture who are receiving long-term androgen deprivation therapy (ADT) for prostate cancer, new research shows this population to have a higher fracture incidence following treatment completion.